- Home
- RMM vs STRO Comparison
RMM vs STRO Comparison
Compare RMM & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMM | STRO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 524.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMM | STRO |
|---|---|---|
| Price | $14.51 | $28.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 41.0K | ★ 291.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.35 | $0.67 |
| 52 Week High | $14.88 | $43.85 |
Technical Indicators
Market Signals| Indicator | RMM | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 42.12 |
| Support Level | $13.87 | $10.50 |
| Resistance Level | $14.61 | $43.85 |
| Average True Range (ATR) | 0.19 | 3.21 |
| MACD | 0.02 | -1.22 |
| Stochastic Oscillator | 76.43 | 22.83 |
Price Performance
Historical ComparisonAbout RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.